Jonathan Allan sold $186k of STOK
GENERAL COUNSEL & CORP SEC at Stoke Therapeutics, Inc.. 13,666 shares at an average of $13.61, traded Dec 9, 2024, filed Dec 11, 2024.
Score components
- +15RoleOfficer
- +12Trade size$186k at market
- +10Share of holdings soldSold 39% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-028929, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2024 | SOpen-market sale Common Stock10b5-1 | -12,114 | $13.69 | $166k | 23,028 | Dec 11, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stock10b5-1 | -1,552 | $12.99 | $20k | 21,476 | Dec 11, 2024 |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 8Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $27k 1,051 shares | -5% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 31Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $128k 3,978 shares | -25% | |
| 32Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $433k 13,430 shares | -21% | |
| 19Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $306k 9,803 shares | -38% | |
| 17Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $467k 15,001 shares | -19% | |
| 31Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $138k 4,576 shares | -19% | |
| 23Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $65k 2,136 shares | -4% | |
| 40Moderate | Stoke Therapeutics, Inc. | Adrian R. Krainer director | $1.2M 40,472 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.